Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan may reveal early clues to Alzheimer's

NCT ID NCT04251130

Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study is looking at how a protein called tau builds up in the brains of older adults with mild cognitive impairment (MCI) or who are cognitively normal. Researchers will use a special PET scan with a tracer called [18F]PI-2620 to take detailed pictures of the brain's memory center. The goal is to see if tau buildup is linked to thinning of brain tissue in areas important for memory. This is a knowledge-gathering study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]PI-2620 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could help doctors better understand and detect early signs of Alzheimer's disease using brain scans.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct benefit for participants, and the imaging technique may not prove useful in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults cognitively normal or Mild Cognitive Impairment (MCI) or Alzheimer's Disease.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females ≥ 60 years of age. * Part of the NACC longitudinal cohort (IRB# 068200) of the PMC/ADCC with consensus conference designation of cognitively normal or Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Possible or Probable. * NACC longitudinal visit completed or scheduled within 6 months before or after enrollment in this study. * Women must be post-menopausal or surgically sterile. * An amyloid PET scan, completed as a part of the NACC protocol (IRB# 825943), must be performed or scheduled within 12 months before or after the \[18F\]PI-2620 PET scan. * A brain MRI, completed as a part of NACC protocol (IRB# 068200), must be performed or scheduled within 6 months before or after the \[18F\]PI-2620 PET scan. Scan should be of adequate research quality, including 3 Tesla and/or 7 Tesla high-resolution imaging of MTL structure. Exclusion Criteria: * Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. * Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan. * Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. * Have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported. The inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (EPIC or the ADC database)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment

Contacts and locations

Locations

  • University of Pennsylvania, School of Medicine

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.